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KEY POINTS
 Large, multicenter, randomized controlled trials have demonstrated the safety and effi-
cacy of rotigotine 24-hour transdermal system for the treatment of motor symptoms asso-
ciated with both early and advanced Parkinson’s disease (PD).
 In addition to the significant improvements in motor function and reductions in off-time,
nonmotor symptoms, such as sleep, mood, and quality of life, were significantly improved
with rotigotine.
 Adverse events (AEs) were typical of those seen with other dopamine agonists, with the
mostcommonAEs includingapplicationsite reactions, nausea,dizziness, andsomnolence.
 Rotigotine transdermal system is a safe and efficacious treatment option in patients with
early PD as monotherapy and as adjunct to levodopa in patients with more advanced PD.INTRODUCTION
Rotigotine (Neupro) is a nonergot dopamine agonist delivered through a 24-hour
transdermal system. It is approved in the United States and multiple European coun-
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Lyons & PahwaS52treatment, rotigotine is initiated at 2 mg/24 h and increased by 2-mg/24 h increments
as needed to a maximum dose of 6 mg/24 h. For advanced treatment, rotigotine is
initiated at 4 mg/24 h and increased by 2-mg/24 h increments as needed, up to a
maximum dose of 8 mg/24 h. In European countries, the maximum approved dose
for early disease is 8 mg/24 h and the maximum approved dose for advanced disease
is 16 mg/24 h. For the treatment of PD, rotigotine is available in patch strengths of
2 mg/24 h (4.5 mg/d or 10 cm2), 4 mg/24 h (9 mg/d or 20 cm2), 6 mg/24 h
(13.5 mg/d or 30 cm2), and 8 mg/24 h (18 mg/d or 40 cm2). Randomized, double-
blind, placebo-controlled trials have demonstrated the safety and efficacy of rotigotine
in the treatment of both early and advanced motor symptoms and some nonmotor
symptoms of PD.
EARLY PARKINSON’S DISEASE TRIALS
The Parkinson Study Group1 conducted a placebo-controlled, double-blind study of
242 patients with early PD randomized to either placebo or daily rotigotine
2 mg/24 h (4.5 mg/d), 4 mg/24 h (9 mg/d), 6 mg/24 h (13.5 mg/d), or 8 mg/24 h
(18 mg/d) for 11 weeks. The mean subject age was approximately 61 years and
PD duration was approximately 1 year. The primary outcome variable, the Unified
Parkinson’s Disease Rating Scale (UPDRS) activities of daily living (ADL) plus motor
score, was improved in each of the rotigotine groups compared with placebo. There
was a dose response, however, and the only significant improvements were seen
with the 6-mg/24 h and 8-mg/24 h doses (Table 1). AEs that were significantly
more common with rotigotine than placebo were typical of a dopamine agonist
and included nausea, somnolence, insomnia, vomiting, and fatigue (Table 2). TheTable 1
Demographics and treatment effects for the UPDRS ADL (part II) plus motor (part III) scores for
randomized, double-blind, controlled trials of rotigotine in early Parkinson’s disease
Study Daily Dosage n
Study
Duration
(wk)
Ageb
(y)
Disease
Durationb
(y)
Treatment
Effect: UPDRS
ADL D Motor
Parkinson
Study
Group,1
2003
Rotigotine
(2 mg/24 h)
49 11 62 1.2 0.9
Rotigotine
(4 mg/24 h)
47 11 61 1.5 2.8
Rotigotine
(6 mg/24 h)
48 11 61 1.2 4.8a
Rotigotine
(8 mg/24 h)
51 11 61 1.1 5.2a
Placebo 47 11 62 1.3
Watts et al,2
2007
Rotigotine (mean
dose 5.7 mg/24 h)
181 24 62 1.3 5.3a
Placebo 96 24 64 1.4
Giladi et al,4
2007
Rotigotine (mean
dose 7.2 mg/24 h)
215 33 61 1.4 5.0a
Ropinirole (median
dose 14 mg/d)
228 24 62 1.3 8.8a
Placebo 118 24 60 1.2
a Treatment effect (active drug improvement minus placebo improvement; reduction 5 improve-
ment); P.001.
b Mean values.
Table 2
Percentages of the most common adverse events reported in early and advanced Parkinson’s disease randomized, controlled, double-blind clinical trials of
rotigotine
Study Dose (mg/24 h) ASR Dizziness Fatigue Hallucination Headache Nausea
Peripheral
Edema Somnolence Vomiting
Early PD
Parkinson
Study Group,1
2003
Rotigotine (2) 27 27 14 2 16 41 2 18 12
Rotigotine (4) 26 19 23 2 23 45 4 21 17
Rotigotine (6) 46 25 6 2 13 50 6 23 21
Rotigotine (8) 59 24 16 2 18 53 6 24 16
Placebo 21 13 2 0 13 15 0 4 2
Watts et al,2 2007 Rotigotine mean dose (5.7) 44 19 8 0 16 41 3 33 33
Placebo 12 13 5 1 9 17 3 20 20
Giladi et al,4 2007 Rotigotine mean dose (7.2) 38 14 NR NR 10 29 NR 23 12
Ropinirole median dose (14) 7 17 NR NR 9 36 NR 28 11
Placebo 11 10 NR NR 8 16 NR 20 3
Advanced PD
LeWitt et al,6 2007 Rotigotine (8) 36 23 NR 7 10 28 9 32 See nausea
Rotigotine (12) 46 15 NR 14 8 24 14 32 See nausea
Placebo 13 15 NR 3 8 20 <1 28 See nausea
Poewe et al,8 2007 Rotigotine mean dose (12.9) 18 6 NR 5 4 17 NR 12 NR
Pramipexole mean dose (3.1) 6 10 NR 7 7 13 NR 12 NR
Placebo 9 4 NR 1 5 11 NR 8 NR
All values reported as percentages.
Abbreviations: ASR, application site reaction; NR, not reported.
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Lyons & PahwaS54majority of AEs, in particular nausea and vomiting, occurred during the titration
phase. Application site reactions increased as the dose of rotigotine increased,
with the 6-mg/24 h and 8-mg/24 h groups having significantly more reactions
than the placebo group.
Watts and colleagues2 reported a placebo-controlled, double-blind, 24-week study
in which patients with early PD were randomized in a 2:1 fashion to either rotigotine or
placebo, respectively. In the rotigotine group, subjects were started with 2 mg/24 h
(4.5 mg/d) and the dose was increased to 6 mg/24 h (13.5 mg/d), as tolerated. The
mean dose of rotigotine at 24 weeks was 5.7 mg/24 h (12.8 mg/d). Mean age was
approximately 63 years and disease duration was approximately 1 year. The primary
outcome variable was UPDRS ADL plus motor score after a 24-week maintenance
period. There was a significant treatment effect of 5.3 points with a 4-point improve-
ment in the rotigotine group and a worsening of approximately 1 point in the placebo
group. AEs were typical of a dopamine agonist and those that were significantly more
common with rotigotine compared with placebo were application site reactions,
nausea, somnolence, dizziness, and headache (see Table 2).
The results of an open-label study3 enrolling 216 subjects from the Watts and
colleagues’2 double-blind, placebo-controlled study were reported after a mean
follow-up of 5.3 years. The mean dose of rotigotine was 7.2 mg/24 h (16.2 mg/d)
and 74% of patients began treatment with levodopa at a mean dose of 374 mg/d.
Initially, the UPDRS ADL plus motor score was improved by 5.6 points compared
with the baseline score in the double-blind study. By 2 years, however, the scores
were not different from the double-blind baseline. For the remaining 4 years of
follow-up, UPDRS ADL plus motor scores worsened but remained within 4 points of
the double-blind baseline scores. The most common AEs with rotigotine treatment
during the follow-up period were somnolence (54%), falls (33%), peripheral edema
(37%), application site reactions (32%), nausea (31%), and dizziness (27%). The
majority of the AEs were mild to moderate, with only 5% severe.
The Study on the Use of Rotigotine in Early Parkinson’s Disease (SURE-PD)4 was a
double-blind, double-dummy, placebo-controlled, and ropinirole-controlled study of
early PD. Subjects were randomized in a 2:2:1 fashion to rotigotine, ropinirole, or pla-
cebo, respectively. The maintenance period for the rotigotine group was 33 weeks
compared with 24 weeks for ropinirole and placebo, due to the longer titration period
for ropinirole. The majority of subjects randomized to rotigotine (92%) received the
maximum 8-mg/24 h (18-mg/d) dose and the median dose of ropinirole was
14 mg/d, with 26% receiving the maximum dose of 24 mg/d. The primary outcome
variable was the percentage of responders, defined as those with at least a 20%
improvement in UPDRS ADL plus motor scores. The rotigotine (52%) and ropinirole
(68%) groups both had significantly more responders than the placebo group (30%).
There were also significant improvements with rotigotine and ropinirole in UPDRS
ADL plus motor scores compared with placebo (see Table 1). The study was not
powered to compare rotigotine and ropinirole directly and the analyses were not
able to show that rotigotine was not inferior to ropinirole when subjects taking up
to 8 mg/24 h (18 mg/d) of rotigotine were compared with those taking up to
24 mg/d of ropinirole. Post hoc analyses demonstrated that when subjects taking
up to 8 mg/24 h of rotigotine were compared with those taking up to 12 mg/d of ropi-
nirole (half the maximum dose), efficacy was similar, with UPDRS ADL plus motor
score change from baseline of 7.2 for the rotigotine group and 9.0 for the ropinirole
group. AEs more common with rotigotine than placebo included application site
reactions, nausea, vomiting, somnolence, dizziness, and headache. AEs for rotigo-
tine and ropinirole were similar (see Table 2).
Outcomes of Rotigotine Clinical Trials S55In summary, 3 randomized, controlled, double-blind studies have confirmed the
safety and efficacy of transdermal rotigotine as a once-daily treatment for early PD.
There seems to be a dose response with the treatment effect for the combined UPDRS
ADL, with motor scores significant for the 6-mg/24 h and 8-mg/24 h dosages but not
for the 2-mg/24 h and 4-mg/24 h dosages. There are no controlled data comparing
rotigotine efficacy to that of other dopamine agonists. In one study,4 rotigotine and
ropinirole were both significantly more efficacious than placebo; however, the study
was not powered to compare these treatments directly. AEs were similar to those
of other dopamine agonists used in the treatment of early PD, except for the occur-
rence of application site reactions. Movement Disorder Society evidence-based
guidelines5 found rotigotine clinically useful and efficacious as a symptomatic mono-
therapy and to have an acceptable risk without specialized monitoring.
ADVANCED PARKINSON’S DISEASE TRIALS
The prospective randomized evaluation of a new formulation: efficacy of rotigotine
(PREFER) study6 was a randomized, double-blind, placebo-controlled study in PD pa-
tients with at least 2.5 hours of off-time per day. Subjects received rotigotine 8mg/24 h
(18 mg/d) or 12 mg/24 h (27 mg/d) or placebo for 24 weeks. The primary outcome var-
iable was the change in daily off-time as measured by patient diaries (Table 3). Off-
time was significantly decreased in the rotigotine 8-mg/24 h group by 2.7 hours and
in the rotigotine 12-mg/24 h group by 2.1 hours, and there was a nonsignificant
decrease of 0.9 hour in the placebo group. Similarly, on-time without troublesome
dyskinesia was increased by 3.5 hours per day in the rotigotine 8-mg/24 h group,
2.2 hours per day in the rotigotine 12-mg/24 h group, and 1.1 hours per day with pla-
cebo. UPDRS ADL scores were significantly improved with rotigotine 8 mg/24 h (3.1
points) and 12 mg/24 h (3.2 points) compared with placebo (0.5 point). UPDRS motor
scores were also significantly improved in the rotigotine 8-mg/24 h group (6.8 points)
and the 12-mg/24 h group (8.7 points) compared with placebo (3.4 points). AEs wereTable 3
Demographics and treatment effects for daily off-time, the UPDRS ADL (part II) and UPDRS
motor (part III) scores for randomized, double-blind, controlled trials of rotigotine in
advanced Parkinson’s disease
Study Daily Dosage n
Study
Duration
(wk)
Ageb
(y)
Disease
Durationb
(y) Off-time
UPDRS
ADL
UPDRS
Motor
LeWitt et al,6
2007
Rotigotine
(8 mg/24 h)
120 24 66 7.7 1.8a 2.6a 3.4a
Rotigotine
(12 mg/24 h)
111 24 64 7.8 1.2a 2.7a 5.3a
Placebo 120 24 66 7.8
Poewe et al,8
2007
Rotigotine
mean dose
(12.9 mg/24 h)
201 24 64 8.9 1.6a 2.2a 4.4a
Pramipexole
mean dose
(3.1 mg)
200 24 63 8.4 1.9a 2.6a 6.0a
Placebo 100 24 65 8.5
a Treatment effect (active drug improvement minus placebo improvement; reduction 5 improve-
ment); P.02.
b Mean values.
Lyons & PahwaS56typical of a dopamine agonist (see Table 2). Application site reactions increased as the
rotigotine dose increased and both dosages had significantly more reactions than with
placebo. Dyskinesia occurred in 14% of the rotigotine 8-mg/24 h group, 17% of the
rotigotine 12-mg/24 h group, and 7% of the placebo group.
The results of an open-label study7 enrolling 258 subjects from the PREFER6
double-blind, placebo-controlled study were reported after a follow-up of up to
6 years. The mean dose of rotigotine was 4.5 mg/24 h (10.1 mg/d) and the mean
dose of levodopa was 1530 mg/d. Initially, the UPDRS ADL score was improved by
4.9 points compared with the baseline score in the double-blind study. By the end
of treatment, however, the scores had worsened by 4.1 points compared with the
double-blind baseline. The UPDRS motor scores initially improved by 11.4 points
compared with the double-blind baseline but were not different from the double-
blind baseline at end of treatment (0.2-point improvement). The most common AEs
with rotigotine treatment during the follow-up period were somnolence (58%), falls
(40%), and application site reactions (33%). During the open-label study, 80% devel-
oped dyskinesia.
Clinical EfficacyofPramipexole andTransdermalRotigotine inAdvancedParkinson’s
Disease (CLEOPATRA-PD)8 was a 24-week, randomized, double-blind, double-
dummy, placebo-controlled study in PD patients with at least 2.5 hours of daily
off-time. In this study, the change in daily off-time with rotigotine less than or equal to
16 mg/24 h (36 mg/d), pramipexole less than or equal to 4.5 mg/d, and placebo was
compared. At 24 weeks, the mean daily dose of rotigotine was 12.95 mg/24 h
(29mg/d) and themean dose of pramipexole was 3.1mg/d. Daily off-timewas reduced
by 2.5 hours with rotigotine, 2.8 hours with pramipexole, and 0.9 hours with placebo.
Off-time reductions for rotigotine and pramipexole were significantly different than pla-
cebo; however, there was no difference between the 2 treatment groups. Similarly,
UPDRS ADL and motor scores were significantly reduced with both pramipexole and
rotigotine compared with placebo and there were no differences between the 2 treat-
ments (see Table 3). The results of the 39-question Parkinson’s Disease Questionnaire
(PDQ-39) at 24 weeks demonstrated no differences between rotigotine and pramip-
exole; however, both treatments had significant improvements comparedwith placebo
in the total score and subscores of mobility, ADLs, and emotional well-being. The Par-
kinson’s Disease Sleep Scale (PDSS), a 15-item visual analog scale completed by sub-
jects to measure the profile of nocturnal disturbances, was also significantly improved
with pramipexole and rotigotine treatments comparedwith placebo. Therewere no sig-
nificant differences between rotigotine and pramipexole. AEswere similar in the 2 treat-
ment groups (see Table 2). Dyskinesia occurred in 12% receiving rotigotine, 15%
receiving pramipexole, and 3% receiving placebo. Application site reactions and
nausea were more common with rotigotine than with either pramipexole or placebo.
In contrast, dyskinesia, dizziness, and hallucinations were more common with prami-
pexole than with rotigotine or placebo.
The results of an open-label study7 enrolling 395 subjects from the CLEOPATRA-
PD8 double-blind, placebo-controlled study were reported after a follow-up of up to
4 years. The mean dose of rotigotine was 5.2 mg/24 h (11.6 mg/d) and the mean
dose of levodopa was 1408 mg/d. Initially, the UPDRS ADL score was improved by
4.5 points compared with the double-blind baseline score. By the end of treatment,
however, the scores had worsened by 0.8 points compared with the double-blind
baseline. The UPDRS motor scores initially improved by 10.1 points compared with
the double-blind baseline and by the end of the study they were improved by only
2.8 points compared with the double-blind baseline. The most common AEs with roti-
gotine treatment during the follow-up period were somnolence (34%), falls (16%),
Outcomes of Rotigotine Clinical Trials S57and application site reactions (26%). During the open-label study, 69% developed
dyskinesia.
In summary, 2 randomized, controlled, double-blind studies have confirmed the
safety and efficacy of transdermal rotigotine as a once-daily treatment of patients
with advanced PDwith motor fluctuations. When adjusting for the placebo effect, daily
off-time was reduced by 1.6 to 1.8 hours per day. UPDRS ADL scores improved by 2.2
to 2.7 points after 24 weeks and UPDRS motor scores improved by 4.4 to 5.3 points
when compared with placebo. Quality of life as measured by the PDQ-39 and
nocturnal difficulties as measured by the PDSS were both significantly improved
with rotigotine compared with placebo. When compared with pramipexole, both
dopamine agonists significantly reduced daily off-time and improved motor function,
quality of life, and sleep, but there were no significant differences between the 2 drug
treatments. AEs were similar to those of other dopamine agonists used for the treat-
ment of advanced PD, except for the occurrence of application site reactions. The
Movement Disorder Society evidence-based guidelines5 found rotigotine clinically
useful and efficacious as a symptomatic adjunct to levodopa and as treatment of
motor fluctuations. Rotigotine was determined to have an acceptable risk without
specialized monitoring.NONMOTOR SYMPTOM TRIAL
The Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
(RECOVER)9 study focused on PD patients with and without motor fluctuations and
with poor control of early morning PD symptoms. Subjects were randomized in a
2:1 fashion to receive either rotigotine (16 mg/24 h or 36 mg/d) or placebo, respec-
tively. In the final analyses, 178 subjects received rotigotine and 89 received placebo.
The mean age of the subjects was 64 years and mean disease duration was approx-
imately 5 years. The primary outcome measures were the change in motor function in
the early morning as measured by the UPDRS motor score and change in sleep and
nocturnal disability as measured by the revised patient-reported PDSS (PDSS-2).
There was a titration period of up to 8 weeks and a 4-week maintenance period, after
which assessments were completed and compared with baseline.
RECOVER included subjects with either early or more advanced PD; therefore, not
all subjects were taking levodopa. The outcomes were analyzed based on levodopa
usage and use of levodopa did not have a significant effect. Early morning UPDRS
motor scores were significantly improved by 3.6 points and PDSS-2 scores were
improved by 4.3 points with rotigotine compared with placebo. The PDSS-2 signifi-
cantly improved with rotigotine compared with placebo in the 3 domain scores, which
included disturbed sleep, motor symptoms at night, and PD symptoms at night. Indi-
vidual items demonstrating significant improvements with rotigotine compared with
placebo included difficulty falling asleep, being tired/sleepy in the morning, restless-
ness of arms or legs, urge to move arms or legs, painful posturing in the morning,
tremor on waking, feeling uncomfortable and immobile, pain in arms or legs, muscle
cramps in arms or legs, and breathing problems/snoring. Distressing hallucinations
was the only item that showed no improvement with rotigotine. The Nocturnal
Akinesia, Dystonia and Cramps Score also indicated subjects had significantly
improved with rotigotine compared with placebo. There was no change in nocturia,
however, with rotigotine compared with placebo.
Other nonmotor symptoms were also assessed in RECOVER. The PD nonmotor
symptom assessment scale total score was significantly improved with rotigotine
compared with placebo. Nonmotor symptom subscale scores, which included
Lyons & PahwaS58sleep/fatigue and mood/cognitions, significantly improved with rotigotine. There
were no significant changes in cardiovascular, perception/hallucinations, attention/
memory, gastrointestinal tract, urinary, sexual function, or miscellaneous subscale
scores. There were also significant improvements with rotigotine compared with
placebo in the Beck Depression Inventory, Likert pain scale, PDQ-8 quality-of-life
assessment (a short, 8-item measure derived from the PDQ-39), and UPDRS ADL
scores. This study demonstrated that 24-hour transdermal rotigotine can lead not
only to significant improvements in motor function but also significant improvements
in nonmotor symptoms, such as sleep, mood, depression, pain, and quality of life.9
The most common AEs in the RECOVER study were similar to those in other rotigo-
tine studies. Nausea occurred in 21% of subjects receiving rotigotine and 9%
who were administered placebo; application site reactions occurred in 15% of
rotigotine-treated and 4% of placebo-treated subjects; dizziness in 10% receiving
rotigotine and 6% receiving placebo; dyskinesia in 8% administered rotigotine and
4% administered placebo; and headache in 7% of rotigotine-treated and 5% of
placebo-treated subjects.9SUMMARY
In summary, large, multicenter, randomized, controlled trials have demonstrated the
safety and efficacy of rotigotine 24-hour transdermal system for the treatment of
motor symptoms associated with both early and advanced PD. In addition to the sig-
nificant improvements in motor function and reductions in off-time, nonmotor symp-
toms, such as sleep, mood, and quality of life, were significantly improved with
rotigotine. AEs were typical of those seen with other dopamine agonists, with the
most common AEs including application site reactions, nausea, dizziness, and som-
nolence. Rotigotine transdermal system is a safe and efficacious treatment option in
patients with early PD as monotherapy and as adjunct to levodopa in patients with
more advanced PD.REFERENCES
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